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Abstract
Monoclonal antibodies specific for cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4) are a novel form of cancer
immunotherapy. While preclinical studies in mouse tumor models have shown anti-tumor efficacy of anti-CTLA4 injection or
expression, anti-CTLA4 treatment in patients with advanced cancers had disappointing therapeutic benefit. These
discrepancies have to be addressed in more adequate pre-clinical models. We employed two tumor models. The first model
is based on C57Bl/6 mice and syngeneic TC-1 tumors expressing HPV16 E6/E7. In this model, the HPV antigens are neo-
antigens, against which no central tolerance exists. The second model involves mice transgenic for the proto-oncogen neu
and syngeneic mouse mammary carcinoma (MMC) cells. In this model tolerance to Neu involves both central and peripheral
mechanisms. Anti-CTLA4 delivery as a protein or expression from gene-modified tumor cells were therapeutically efficacious
in the non-tolerized TC-1 tumor model, but had no effect in the MMC-model. We also used the two tumor models to test an
immuno-gene therapy approach for anti-CTLA4. Recently, we used an approach based on hematopoietic stem cells (HSC) to
deliver the relaxin gene to tumors and showed that this approach facilitates pre-existing anti-tumor T-cells to control tumor
growth in the MMC tumor model. However, unexpectedly, when used for anti-CTLA4 gene delivery in this study, the HSC-
based approach was therapeutically detrimental in both the TC-1 and MMC models. Anti-CTLA4 expression in these models
resulted in an increase in the number of intratumoral CD1d+ NKT cells and in the expression of TGF-b1. At the same time,
levels of pro-inflammatory cytokines and chemokines, which potentially can support anti-tumor T-cell responses, were
lower in tumors of mice that received anti-CTLA4-HSC therapy. The differences in outcomes between the tolerized and non-
tolerized models also provide a potential explanation for the low efficacy of CTLA4 blockage approaches in cancer
immunotherapy trials.
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Introduction
Activation of T-cells requires recognition of antigens presented
in complex with CD80 and CD86. These costimulatory molecules
interact with CD28, which is constitutively expressed on T cells
and triggers T-cell activation. Once activated, T-cells transiently
up-regulate cytotoxic T lymphocyte–associated antigen 4 (CTLA4)
on their cell surface. CTLA4 shares structural features with the
costimulatory receptor CD28 and reciprocally targets the same
costimulatory molecules (CD80/86) on the antigen-presenting cell,
but with higher affinity. This results in inhibition of T-cell
proliferation and IL-2 production. Blocking CTLA4 with anti-
CTLA4 antibodies enhances effector T-cell responses and can
induce T-cell mediated rejection of certain tumors in mouse
models [1,2,3,4]. Monoclonal antibodies specific for cytotoxic T
lymphocyte-associated antigen 4 (CTLA4) are a form of
experimental immunotherapy for treatment of patients with
advanced cancers, including melanoma, prostate cancer, renal
cell carcinoma, non-Hodgkin’s lymphoma, colorectal carcinoma,
non-small lung breast cancer, and pancreatic cancer [5]. Two fully
humanized monoclonal antibodies, ipilimumab (MDX-010, Me-
darex) and tremelimumab (CP-675,206, Pfizer), have been
investigated in cancer [6,7]. A Phase III trial of tremelimumab
has been halted after it failed to demonstrate superior therapeutic
activity over standard chemotherapy in advanced melanoma
patients. The discrepancy in pre-clinical and clinical studies with
anti-CLTA4 antibodies requires more mechanistic studies in
adequate pre-clinical models. A potential mechanism by which
anti-CTLA4 may provide an antitumor response is through
depletion of regulatory T-cells (Tregs), as Tregs have constitutive
expression of CTLA4 and are known to have suppressive activity.
Alternatively, CTLA4 blockade may activate effector T-cells
allowing them to be more resistant to Treg suppression. Recent
studies indicate that anti-CTLA4 induce immune responses
mainly by direct activation of effector T-cells rather than by
affecting Tregs [8,9].
In this study, we used two tumor models that assess anti-CTLA4
antibody therapy. The first is a murine cervical cancer model
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1 tumors. In this model, the HPV antigens represent neo-antigens
against which no central tolerance mechanisms exit in mice. Most
studies on the mechanisms of immune-activation by CTLA4-
blocking antibodies have been performed in such ‘‘non-tolerized’’
models [10,11,12,13]. In humans, however, most tumor-associated
antigens (TAAs) are non-mutated self-antigens, which are
overexpressed or re-expressed on cancer cells. Several mechanisms
of central and peripheral tolerance therefore exist against self-
TAAs that blunt T-cell responses. Tolerance against TAA has to
be considered in tumor models that are used to delineate the anti-
tumor mechanisms of anti-CTLA4 antibodies. This is accom-
plished in our second animal model, based on neu-transgenic (neu-
tg) mice. These mice overexpress the rat protooncogene Neu and
develop spontaneous mammary tumors between 4 and 8 months
of age [14,15]. Mouse mammary carcinoma cells (MMC) are a
transplantable carcinoma line derived from a spontaneous
mammary tumor from neu-tg mice. The neu-tg/MMC model has
significant biologic and pathologic similarity to human neu-
associated estrogen receptor-negative breast cancer. MMC tumors
are resistant to doxorubicin, hormone therapy, and Neu-specific
mAbs. The tumor antigen repertoire in MMC-tumor bearing mice
appears to be predictive for human breast cancer antigens.
Importantly, neu-tg mice mimic central/peripheral tolerance to an
endogenous tumor antigen that is seen in cancer patients. In this
context, Neu-targeted vaccines, which raise strong CD8-T cell
responses to a dominant peptide (RNEU420-429) in (non-
tolerized) WT FVB/N mice and protect them from a neu-
expressing tumor challenge, fail to do so in neu-transgenic mice.
The latter suggests significant differences between tolerized and
non-tolerized tumor models, which have to be considered in
testing the effect of new immunotherapy agents.
For delivery of anti-CTLA4 immunotherapy, we used three
different approaches; i) systemic application of a monoclonal
antibody against murine CTLA4 (4F10), ii) intratumoral expres-
sion of a secreted form of this antibody from genetically modified
tumor cells, iii) expression of the anti-CTLA4 antibody after gene
delivery using a stem cell based approach.
The central findings from our studies are i) anti-CTLA4 therapy
is inefficient in the tolerized MMC model and ii) in both tumor
models, anti-CTLA4 expression mediated by the HSC delivery
approach not only failed to exert anti-tumor effects, but increased
the rate of tumor growth. Our data suggests that the latter involves
an increase in intratumoral CD1d+ NKT cells, production of
IFNb1, as well as suppression of cytokines and chemokines that
are involved in mediating anti-tumor immune responses. Our
findings shed light on the complexity of immune regulation,
specifically in the context of anti-CTLA4 therapy.
Materials and Methods
Anti-CTLA4 antibodies
Monoclonal antibodies against mouse CTLA4 were purified
from the supernatant of UC10-F10-11 hybridoma cells (ATCC) as
described previously [16].
Lentivirus vectors
The anti-CTLA4 scFv was cloned from total RNA isolated from
UC10-F10-11 hybridoma cells (ATCC). Leucine residues at
positions 43 and 89 in the 4F10 variable region light chain
sequence were mutated to methionine and glutamine, respectively,
to increase scFv expression [17]. The anti-CTLA4 scFv was
inserted into pHook (Invitrogen, Carlsbad, CA) immediately after
the Vk leader sequence and HA epitope tag and before the myc
epitope and platelet-derived growth factor receptor transmem-
brane domain. A stop codon was introduced immediately after the
myc epitope to allow secretion of the antibody. The cDNA
fragment coding the hinge-CH2-CH3 of human IgG1 was inserted
between the scFv and myc epitope. The entire anti-CTLA4
cassette was then transferred into pLVPT-rTRKRAB [18] to
generate pLVaCTLA4. To create the construct for the insulated
vector (I-LV-aCTLA4), the aCTLA-4, IRES, tetR-KRAB and
WPRE from pLVaCTLA4 was transferred into pLenti-cHS-PGK
[19] containing a 0.4 kb fragment of the chicken HS4 insulator
within the 39 LTR. VSV-G pseudotyped viruses were generated as
described earlier [20]. Genome titers were measured by qPCR
and ranged from 1-5610
7 genomes/ml.
Cells
Mouse mammary carcinoma (MMC) cells were established
from a spontaneous tumor in a neu-tg mouse [21]. TC-1 cells were
from the American Type Culture Collection (ATCC) Culture
conditions for MMC and TC-1 cells were RPMI-1640 medium
containing 10% fetal bovine serum (FBS), 2 mM L-glutamine
(Gln), 100 U/ml penicillin (P), and 100 mg/ml streptomycin (S).
To obtain mouse HSCs, donor mice were injected with 5-FU
(150 mg/kg) i.v. two days before bone marrow isolation. Bone
marrow cells were cultured for three days in IMDM, 18%FBS, 5%
mIL-3 (BD Biosciences, San Jose, CA), 100 U/ml mIL-6, 50 U/
ml SCF (PeproTech, Rocky Hill, NJ), P/S, and Gln. Non-
adherent cells were collected and incubated with lentivirus vectors
at an MOI of 2 genomes/cell on retronectin-coated plates for two
days.
Animal studies
All experimental procedures involving animals were conducted
in accordance with the institutional guideline set forth by the
University of Washington. Neu-transgenic (neu-tg) mice [FVB/N-
Tg(MMTVneu)202 Mul] were obtained from the Jackson Labo-
ratory (Bar Harbor, ME). These mice harbor non-mutated, non-
activated rat neu under control of the mouse mammary tumor virus
(MMTV) promoter. The neu transgene is expressed at low levels in
normal mammary epithelium, salivary gland, and lung. Until the
age of 8 months ,35% of female neu-tg mice spontaneously
develop mammary carcinomas that display high Neu-expression
levels. CTLs specific for the immunodominant H-2 Dq/
RNEU420–429 epitope can be detected in neu-tg mice using the
corresponding tetramer [22]. For HSC transplantation, a total of
1610
6 of whole bone marrow cells or lineage cell depleted bone
marrow cells from 5-FU treated mice were transplanted into
lethally irradiated (1050 cGy) female neu-tg mice. Six weeks after
bone marrow transplantation, the mice received 5610
5 MMC or
5610
4 TC-1 cells via subcutaneous injection. Tumors were
measured every other day and tumor volume was calculated as
the product of length x width x width. For survival studies tumor
sizes $500 mm
3 were considered the experimental endpoint.
Animals with skin surface ulcerations were excluded from
experiments and sacrificed immediately.
Anti-CTLA4 antibody ELISA
Two-fold serial dilutions of the culture medium were incubated
for 45 minutes in 96-well microtiter plates previously coated with
500 ng/well recombinant CTLA4 protein [16]. After washing, the
wells were incubated with biotin-labeled anti-HA antibody
(Roche, Mannheim Germany), followed by streptavidin-HRP
(Jackson ImmunoResearch Laboratories) and finally 1-Step
TM
Ultra TMB-ELISA (Thermo Scientific, Rockford, IL) substrate for
Anti-CTLA4 Antibody Therapy
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e2230330 min at room temperature. The absorbance of wells (405 nm)
was measured with a microplate reader.
Mouse cytokine array
Pieces of tumor were homogenized in Complete Lysis Buffer M
(Roche) using TissueRuptor (Qiagen). The total protein concen-
tration was determined using the Protein Assay reagent from Bio
Rad. For each sample, 100 mg were assayed and the Cytokine
Array Panel A (R&D Systems) was performed according to
manufacturer’s suggestions. For the development of the assay,
ECL Plus (GE Healthcare) was used together with Amersham
Hyperfilm ECL (GE Healthcare). The developed films were
scanned and intensities were quantified with SigmaGel (Jandel
Scientific, San Rafael, CA).
Anti-CTLA4 mRNA
mRNA isolation from MMC-Rlx cells and qRT-PCR was
performed as described recently [23]. cDNA was synthesized using
the QuantiTect Reverse Transcription Kit (Qiagen). For PCR the
SYBR Kit (Bioline, Taunton, MA) and the following primers were
used
aCTLA4, fw 59- ACC CCT CAC AAT CAC TGT CC -39
aCTLA4, rev 59- CAC CTG CAG GAA GAA CTG GT -39
Anti-CTLA4 mRNA was equalized to levels of GAPDH mRNA
measured in parallel in each sample. Ct values were calculated
using the Sequence Detection System software (Applied Biosys-
tems). The difference between the number of PCR cycles required
for the two samples to reach a certain fluorescence signal shows
how much of the mRNA of interest is present in the two samples
relative to each other. Each cycle difference is equal to a fold
difference of 2.
qRT-PCR TGF-b1
Pieces of tumor were homogenized using TissueRuptor
(Qiagen) and total RNA was purified with miRQURY RNA
Isolation Kit (Exiqon, Woburn, MA). RNA concentration was
measured on a NanoDrop ND-1000 (Thermo Scientific).
Generation of cDNA was done with QuantiTect Reverse
Transcription Kit (Qiagen) and the qPCR reaction was run, in
triplicates, on a 7900HT Fast Real-Time PCR System (Applied
Biosystems/Life Technologies) using the SensiMix SYBR Kit
(Quantace, London, UK).
Primers (synthesized by Integrated DNA Technologies):
mTGFB1 fw 59-GGCTACCATGCCAACTTCTG -39
mTGFB1 rev 59-CGCACAATCATGTTGGACA -39
mTGFB2 fw 59-TGAGGTGTGAATGCAAGGAG-39
Figure 1. Effect of anti-CTLA4 antibody injection on MMC and TC-1 tumor growth. A) C57Bl/6 mice with subcutaneous TC-1 tumors were
injected with 100 mg anti-CTLA4 and control IgG antibody intraperitoneally (i.p.) every other day. Treatment was started when tumor reached a
volume of 50 mm
3. Tumor volumes were measured thrice a week. Each line represents an individual animal. p,0.05 for time points after day 16. B)
neu-transgenic mice with subcutaneous MMC tumors were treated as described in A). The difference between the two groups was not significant.
doi:10.1371/journal.pone.0022303.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22303Figure 2. Lentivirus vectors expressing anti-CTLA4. A) Structure of integrated provirus genomes. The vectors contain the gene for the
monoclonal antibody 4F10 (ATCC: UC10-4F10-11) specific to mouse CTLA4. The anti-CTLA4 gene contains an immunoglobulin Vk signal peptide, an
HA epitope, the anti–CTLA4 scFv, the hinge, CH2 and CH3 domains of human IgG1, and a myc epitope. The anti-CTLA4 gene is under the control of a
Anti-CTLA4 Antibody Therapy
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mTGFB3fw 59-GCCATTTCCCTCCTACCCTA-39
mTGFB3 rev 59-CATCCATGATTCCCCAAAAA -39
PCR was carried out as follows: after an initial 10-minute
enzyme activation step at 95uC, 40 amplification cycles were run,
each consisting of 95uC for 15 s and 60uC for 1 min. Lastly, a final
elongation step was performed for two minutes at 60uC. Data was
collected initially and after every incubation at 60uC. Anti-TGF-b
mRNA was equalized to levels of GAPDH mRNA measured in
parallel in each sample.
Analysis of TILs
Three weeks after tumor cell transplantation, mice were
sacrificed and tumors and spleen were harvested. Isolated MMC
tumors were minced and filtered through a 70-mm cell strainer.
Tumor infiltrating lymphocytes (TILs) were then isolated from
tumor cells/erythrocytes by centrifugation in a Ficoll gradient.
TILs as well as splenocytes from tumor-bearing mice were used for
analysis of Neu-specific T-cells using a Neu-tetramer assay. The PE-
labeled H-2Dq/RNEU420–429 (H-2D(q)PDSLRDLSVF) tetra-
mer was obtained from the National Institute of Allergy and
Infectious Diseases MHC Tetramer Core Facility (Atlanta, GA).
Flow cytometry was performed with the following monoclonal
antibodies (final concentration 5 mg/ml): anti-FoxP3-PE (clone
FHK16s, eBiosciences, San Diego, CA), anti-CD4-PE, anti-CD8-
PE, anti-CD8-FITC, anti-CD25-FITC (clone 7D4) (all BD
Biosciences), anti-CD25-FITC (clone PC61.5; eBiosciences), and
NK1.1-FITC (clone PK136, BD Biosciences), anti CD1d-PE
(clone 1B1, BD Biosciences). All samples were treated with Fc-
block (anti–CD16/CD32, BD Biosciences). Corresponding isotope
controls yielded no significant staining.
Immunohistochemistry for mouse tissue and organs
Tumors were embedded in Optimal Cutting Temperature
(OCT) medium and frozen at 280uC. Sections were cut at a
thickness of 8 mm and fixed in methanol:aceton (1:1 v/v) at
220uC for 10 min. Nonspecific binding was blocked by 2% non-
fat dry milk in PBS for 20 min at RT. Primary antibodies were
incubated at RT for 1 h. We used anti-CD1d-biotin (clone 1B1,
BD Biosciences) and anti-NK1.1-FITC (clone PK136, BD
Biosciences) antibodies. For histological assessment of autoimmune
disease, mouse tissues and organs (heart, lung, brain, stomach,
mesenterium, liver, kidney, muscle, skin) were fixed in 10%
formalin and processed for hematoxilin and eosin staining. All
samples were examined by two experienced pathologists for typical
inflammation signs in a blind fashion. Immunohistochemistry for
IgG on kidney sections was performed as described for tumor
sections using a polyclonal, HRP-labeled, anti mouse IgG
antibody (eBiosciences).
Blood analysis
Mouse blood was analyzed using a HemaVet 950FS machine.
Statistical analyses
Statistical significance of in vivo data was analyzed by Kaplan-
Meier survival curves and logrank test (GraphPad Prism Version
4). Statistical significance of in vitro data was calculated by two-
sided Student’s t-test (Microsoft Excel). P values,0.05 were
considered statistically significant. JMP statistical package was
used to perform power analysis and determine the minimal
number of animals per group. Using parameters of alpha=0.05;
power=80%; effect size=50% (80% chance of observing a
difference of 50% in tumor size at a level of significance of 0.05),
we arrived at a minimal group size of 5 for a comparison of two
groups. Therefore, all experiments were performed at least once
with 5 animals per group and, if required, repeated with additional
animals until significance was achieved.
Results
Systemic application of anti-CTLA4 antibody
Clinically, antiCTLA4 antibodies are administered systemically.
For our studies in mouse models, we used a monoclonal antibody
against murine CTLA4 (4F10). Systemic administration of this
antibody has been shown before to trigger tumor-destructive
immune responses in several mouse tumor models [24,25]. As in
those studies, we started injecting anti-CTLA4 or control antibody
when tumors reached a volume of 50 mm
3. Injections were
repeated every other day. While in the TC-1 tumor model, anti-
CTLA4 injection significantly delayed tumor growth, it had no
therapeutic effect in the MMC tumor model (Figs. 1A, B). These
studies indicate that anti-CTLA acts differently in tolerized and
non-tolerized tumor models.
Expression of anti-CTLA4 antibody from tumor cells
While systemic anti-CTLA4 administration is technically
straightforward, it is cost-extensive and also bears the risk of
inducing auto-immune responses [16]. These problems can, in
part, be addressed by gene therapy approaches resulting in
intratumoral expression of genes encoding anti-CTLA4 antibod-
ies. Expression of anti-CTLA4 antibodies inside the tumor has
advantages over systemic administration. Presumably, at sites
where the TAA levels are elevated, such as in the tumor
microenvironment, peripheral tolerizing mechanisms must be
enhanced relative to other tissues. To be most effective, the
concentration of immune-stimulatory molecules should therefore
be high in the tumor environment. Recently, an immunostimu-
latory effect of intratumoral expression of a gene encoding a
secreted form of the anti-CTLA4 antibody has been shown in a
model for autoimmune diabetes [26].
To test our therapy approaches, we generated improved
versions of lentivirus vectors. These vectors are self-inactivating
(SIN), i.e. contain a deletion within the 39LTR, which abolishes
the LTR promoter activity (Fig. 2A). Because it had been shown
that a chromatin insulator derived from the chicken globin locus
tTR-KRAB system [18]. tRT-KRAB bound to tet-operator sequences represses promoters in the vicinity of 3-4 kb. Addition of Dox releases this
repression. The vector also contains a central polypurine tract (cPPT) and a woodchuck hepatitis virus post-transcriptional regulatory element (WPRC).
In the insulated vector version (I-LV-aCTLA4), a 0.4 kb cHS4 insulator element [43] is inserted into the 398 bp U3 promoter/enhancer deletion (U3D).
Upon proviral integration into host genome, the U3 region containing the cHS4 is copied over to the 59 LTR. B) Evaluation of anti-CTLA4 expression
on protein level for clones derived after transduction of MMC cells with LV-aCTLA4 (upper panel) or I-LV-aCTLA4 (lower panel). Solid bars: Dox
induced expression. Clones were treated with Dox and 24 h later anti-CTLA4 was measured by ELISA in culture supernatants. Empty bars (to the right
side of solid bars): non-induced expression levels: supernatant from clones w/o Dox treatment were analyzed by ELISA. (Note, that these bars are not
visible for LV-aCTLA4). Anti-CTLA4 levels in the corresponding populations of transduced cells (Pop) are shown on the right. C) Fold change of anti-
CTLA4 mRNA levels after culture with or without doxycycline for 24 h measured. Clones that expressed the highest levels of anti-CTLA4 protein were
included in this analysis. mRNA was isolated and subjected to qRT-PCR for GAPDH and anti-CTLA4 mRNA. Shown is the fold difference of GAPDH
normalized anti-CTLA4 mRNA levels with and without Dox induction. Standard deviation was less than 10%.
doi:10.1371/journal.pone.0022303.g002
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22303Figure 3. Growth and analysis of tumors derived from tumor cells transduced with LV-aCTLA4. A and B) MMC-aCTLA4 cells were injected
and Dox treatment was started when tumors reached a volume of 50 mm
3. Kaplan-Meier survival studies (cut-off is 1000 mm
3). Dox was delivered
with i.p. injection (A) or drinking water (B). N=5. C) Flow cytometry of tumor infiltrating leukocytes and splenocytes in the MMC-aCTLA4 model. At
day 30, tumors, tumor-draining lymph nodes and spleens were harvested. The percentages of Neu specific CD8+ T-cells were measured by tetramer
assay. Shown are the average percentages of marked cells in all TILs, lymph node cells and splenocytes. Standard deviations were less than 10%.
N=3.D) TC-aCTLA4 cells were injected and Dox treatment was started when tumors reached a volume of 50 mm
3. Kaplan-Meier survival studies (cut-
off is 1000 mm
3). Dox was delivered with drinking water. N=5.
doi:10.1371/journal.pone.0022303.g003
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retrovirus vectors from chromosomal position effects of integration
and from silencing, particularly in HSCs and their progeny
[27,28], we constructed an ‘‘insulated’’ SIN vector (I-LV-
aCTLA4) by inserting the 0.4 kb cHS4 into the 39 LTR. In the
integrated I-LV-aCTLA4 provirus DNA, the transgene cassette is
therefore flanked by two HS4 insulators (Fig. 2A, lower panel). A
corresponding vector without cHS4 insulators was called LV-
Figure 4. Therapy study with LV-aCTLA4/I-LV-aCTLA4 transduced HSCs and induction of transgene expression by Dox in drinking
water. A) Scheme of the experiment: A total of 5610
5 LV-transduced mouse HSCs were transplanted into lethally irradiated neu-tg mice via tail
injection. Six weeks after HSCs engraftment, MMC tumors were established via injection of 5610
5 MMC cells subcutaneously. Selected groups of mice
received Dox in drinking water. B) Therapy study with mice that were transplanted with LV-aCTLA4 or I-LV-aCTLA4 transduced mouse HSCs; Tx(LV-
aCTLA4, and Tx(I-LV-aCTLA4), respectively. Dox (0.2 mg/ml) was added to drinking water of selected groups starting at day 1 after MMC cell
implantation. Each line represents an individual animal. C) Survival of MMC tumor bearing mice. The day tumors reached a volume of 900 mm
3
represented the endpoint in Kaplan-Meier survival studies. N.5.
doi:10.1371/journal.pone.0022303.g004
Figure 5. Therapy study with I-LV-aCTLA4 transduced HSCs and induction of transgene expression by Dox by intraperitoneal
injection. Treatment scheme was as described in Fig.2. Mice received an i.p. injection of PBS or Dox (0.5 mg/mouse in 500 ml PBS) starting at day 7
after MMC cell transplantation and then every other day. A) Tumor volumes, B) Kaplan-Meier survival study (cut-off volume was 700 mm
3). N.5.
doi:10.1371/journal.pone.0022303.g005
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activated by the addition of Dox, and Dox withdrawal ceases anti-
CTLA4 antibody expression. This safety feature was built in to
control potential side effects of anti-CTLA4 by expressing it only
transiently. To functionally validate the vectors and assess the
impact of the cHS4 insulators on position effects of integration, we
infected MMC cells at an MOI of 1 cfu/cell and established clonal
cultures by limited dilution. Anti-CTLA4 protein levels were
measured in supernatants of the population (w/o subcloning) and
20 clones with and without Dox induction (Fig. 2B). There was no
significant difference in induced anti-CTLA4 protein levels
between I-LV-aCTLA4 transduced MMC cell clones and clones
that were transduced with the non-insulated vector. As a more
sensitive means to measure anti-CTLA4 expression we used qRT-
PCR (Fig.2C). The increase in anti-CTLA4 mRNA levels upon
Dox treatment was also not significantly greater in I-LV-aCTLA4
transduced clones compared to LV-aCTLA4 clones (p=0.06).
Overall, these data show that the inclusion of chromatin insulators
into lentivirus vectors did not improve Dox mediated regulation of
transgene expression.
For therapy studies in vivo, we used an MMC cell clone that
stably expressed anti-CTLA4 under Dox control (clone 4
generated from LV-aCTLA4 transduced MMC cells; see
Fig. 2B). MMC-aCTLA4 cells were injected into neu-tg mice.
When tumors reached a volume of 50 mm
3, Dox was given either
intraperitoneally (Fig. 3A) or in drinking water (Fig. 3B) to half of
the mice. Induction of anti-CTLA4 expression in vivo was
confirmed on the mRNA level by qRT-PCR and protein level
by ELISA with tumor lysates (data not shown). Dox induction of
anti-CTLA4 expression in MMC-aCTLA4 cells in vivo did not
prolong survival in both models. Flow cytometry analysis revealed
significantly higher percentage of Neu-specific CD8 cells in the
tumor and tumor-infiltrating lymph nodes in the MMC-
aCTLA4+Dox group compared to the corresponding group that
did not receive Dox (Fig. 3C). Interestingly, Dox induced anti-
CTLA4 expression appeared to increase the percentage of NK
cells in the tumor and spleen. There was no significant difference
in the number of CD4/CD25 cells, i.e Tregs.
For studies with the TC-1 model, we selected a TC1-aCTLA4 cell
clone that produced similar anti-CTLA4 levels as the MMC-
aCTLA4 clone upon Dox induction. In contrast to the study in the
MMC model, anti-CTLA4 expression from TC-1 cells resulted in a
significant delay in tumor growth (Fig. 3D). This is in agreement with
an earlier study, in which we also showed that the anti-tumor effect is
mediated by an increase of tumor-infiltrating IFNc-producing CD8
+
T cells [16]. Again these studies suggest that anti-CTLA4 has no
therapeutic effect in tolerized tumor models, although it appears to
increase the number of intratumoral effector T-cells.
HSC based delivery of anti-CTLA4 gene
Because viral gene transfer to epithelial tumors is inefficient, we
employed a new stem cell based approach to deliver the anti-
CTLA4 gene to the tumor [20]. Both types of tumors have
epithelial features including various intercellular junctions and
extracellular matrix surrounding tumor nests. These physical
barriers limit the efficacy of gene delivery using virus-based vectors
[29,30]. Because of this, stem cell based gene delivery approaches
have been evaluated. In this context, the tropism of mesenchymal
stem cells (MSC) for tumors has been exploited to deliver anti-
tumor cytokine genes using ex vivo gene-modified MSCs [31].
Furthermore, based on the finding that monocytes/macrophages
have the ability to migrate within tissues, even in hypoxic
microenvironments, genetically modified monocytes/macrophag-
es or progenitors have been used to delivery therapeutic genes to
tumors [32]. We have previously developed an approach based on
hematopoietic stem cells (HSCs) for in vivo gene delivery [20]. This
approach is based on the fact that tumor cells secrete a number of
chemokines that actively mobilize myeloid progenitors from the
bone marrow and recruit them to the tumor stroma, where they
differentiate into tumor-associated macrophages (TAMs). TAMs
are critical for tumor survival as they produce factors that trigger/
support tumor growth, neoangiogenesis, immune escape and
stroma development. Our approach involves the ex vivo transduc-
tion of bone marrow derived HSCs with lentivirus vectors that
express the transgene under control of a Doxycyline (Dox)-
inducible transcription cassette, and the transplantation of these
cells into myelo-conditioned recipients, where they engraft in the
bone marrow and provide a long-term source of genetically
modified cells that will home to tumors. This approach allows for
efficient transgene delivery to the center of tumors. For example,
in mice transplanted with HSCs transduced with a GFP expressing
lentivirus vector, ,5% of all cells in MMC tumors were GFP
positive, whereby most of the transgene expressing cells were
TAMs [20,33]. In a recent study, we also showed that the
inducible intratumoral expression of the peptide hormone relaxin
after the transplantation of mouse HSCs transduced with a
relaxin-expressing lentivirus vector, delayed tumor growth in the
MMC-tumor model [20]. Here we used this ‘‘Trojan Horse’’
approach to deliver the anti-CTLA4 antibody gene to TC-1 and
MMC tumors.
Figure 6. HSC-based anti-CTLA4 gene therapy in the TC-1 tumor model. Mice were treated as described in Fig. 4A. The experiment was
terminated at day 18. A) Tumors were excised and measured. N=5. B) Representative excised tumors.
doi:10.1371/journal.pone.0022303.g006
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e22303As a source of HSCs, we used bone marrow cells from mice that
were injected intravenously with 5-FU (150 mg/kg) two days prior
to the collection of bone marrow. Bone marrow cells were cultured
for three days and non-adherent cells (enriched for HSCs and
primitive progenitors) were mock-transduced or transduced with
LV-aCLTA4 or I-LV-aCTLA4 at an MOI of 1 cfu/cell. An
aliquot of transduced HSCs was used to confirm successful
transduction and anti-CTLA4 expression by qRT-PCR on cells
cultured for 2 days. The rest of the cells were transplanted into
lethally irradiated neu-tg mice. Six weeks later, subsequent to the
bone marrow engraftment of genetically modified cells, mice were
subcutaneously injected with MMC cells and Dox was given in
drinking water to selected groups of animals (for a schematic of the
experiment see (Fig. 4A). Mice were followed for 35 days. Animals
were sacrificed before the end of the observation period if the
tumors reached a volume of 1,000 mm
3 or ulcerated. In explanted
tumors, anti-CTLA4 mRNA was measured by qRT-PCR. In mice
that received LV-aCTLA4 transduced HSCs, tumor anti-CTLA4
mRNA levels were 36-fold (+/25) higher in Dox-treated mice
compared to mice that received drinking water without Dox.
There was no significant difference in anti-CTLA4 levels between
LV-aCTLA4 and I-LV-aCTLA4 (Fig. 4B). Tumor volumes of
individual mice and Kaplan-Meier survival studies are shown in
Fig.4C. Unexpectedly, Dox treatment, i.e. induction of anti-
CTLA4 expression in tumors, shortened the survival of mice (Tx(I-
LV-aCTLA4) + Dox vs Tx(I-LV-aCTLA4): p=0.029 and Tx(LV-
aCTLA4) +Dox vs Tx(LV-aCTLA4): p=0.095). Dox treatment of
mock-transplanted mice did not affect MMC tumor growth [20].
To consolidate these findings, we performed a second experiment
where Dox was given intraperitoneally to better control its delivery
to mice (Fig. 5). As seen before, Dox-induced anti-CTLA
expression did not exert therapeutic effects and shortened the
life-span of animals.
In the TC-1 model, so far, injection of anti-CTLA4 or
expression from TC-1 cells significantly delayed tumor growth.
However, when we employed the HSC-based approach for in vivo
expression of anti-CTLA4, we found a marked stimulation of TC-
1 tumor growth upon Dox induction of anti-CTLA4 expression.
Furthermore, tumor growth in the Tx(I-LV-aCTLA4 +Dox)
group was more invasive involving subcutaneous muscle tissues.
Because of this, it was impossible to measure tumor volumes over
time. We therefore show the tumor volumes at the end of the
observation period (day 35) (Fig. 6A). Representative explanted
tumors are show in Fig.6B.
In summary, when the anti-CTLA4 gene was delivered using
the HSC-based approach, it stimulated tumor growth in both
tumor models.
Mechanism of failure of HSC-based anti-CTLA4 therapy
To understand why anti-CTLA4 in these models did not
suppress tumor growth, we performed flow cytometry and
immunofluorescence analyses of immune cells in the spleen and
the tumors. In addition to standard analyses for CD4 T-cells,
NK cells, and Tregs, we also searched for changes in potential
immunosuppressive cells. Among the latter is a specialized
subset of NKT cells [10,34,35]. NKT cells are a unique T-cell
subset expressing both TCR and NK cell receptors. Most NKT
cells are restricted by the MHC class I–like molecule CD1d. In
the mouse, most CD1d+ NKT cells are CD4
+. An involvement
of NKT in mediating tolerance to self-antigens and suppressing
auto-immune inflammatory reactions has been reported in
experimental and human autoimmune diseases [36]. A potential
pathway that leads to immunosuppression involves the secretion
of IL-13 by NKT cells and subsequent activation of Gr-
1+CD11b+ myeloid suppressor cells, which in turn produce
TGF-b1 [37]. In agreement with earlier studies [16], we found
less CD4/CD25+ Tregs in I-LV-aCTLA+Dox tumors and
spleen than in I-LV-aCTLA tumors (Figs. 7A and C).
Importantly, however, both flow cytometry analysis of TILs
(Fig.7A) and immunofluorescence analysis of tumor section
(Fig.7B) showed significantly more CD1d+ cells in TILs of mice
where anti-CTLA4 production was induced by Dox than in
Tx(LV-aCTLA4) mice without Dox treatment and control mice
that received mock transplantation (p=0.026). The majority of
CD1d+ cells in Tx(I-LV-aCTLA+Dox) tumors were CD4 cells
(Fig.7A). Flow cytometry data were supported by costaining of
tumor sections for CD1d and CD4 or NK.1.1 (Fig.7B). Notably,
there was no significant difference in the composition and
percentages of MMC tumor infiltrating leukocytes in Tx(I-LV-
aCTLA) mice (without Dox induction) and mice that did not
receive a bone marrow transplantation. Analysis of splenocytes
of treated animals also showed a significant difference in the
percentage of CD1d+ of I-LV-aCTLA+Dox and I-LV-aCTLA
animals (Fig.7C, D). Figure 7 shows data from studies in the
MMC tumor model. The outcome of studies in the TC-1 tumor
model was similar.
To further elucidate mechanisms of failure of HSC-based anti-
CTLA4 therapy, we analyzed the expression of cytokines and
chemokines in tumors. As TGF-b1 potentially mediates the
immunosuppressive effect of CD11d+ NKT cells, we measured
TGF-b1 mRNA by qRT-PCR in TC1 and TC1-aCTLA4+Dox
tumors (Fig.8A). We found 49+/25-fold higher concentrations of
TGF-b1 mRNA in TC1-aCTLA4+Dox tumors than in TC-1
tumors. RNA levels of TGF-b2 and TGF-b3, i.e. cytokines that
are not involved in immunosuppression did not differ between the
two groups. Other cyto- and chemokines were analyzed by
commercial proteome arrays. (These arrays did not cover TGF-b).
The outcome of these studies was consistent for the TC-1 and
MMC tumor models. In both models, HSC-mediated anti-
CTLA4 expression resulted in a marked decrease of pro-
inflammatory cyto- and chemokines in tumors, including IL-1b,
MIG, MIP-1a, MIP-1b, and RANTES (Figs. 8B-D).
Notably, in all therapy studies, there were no signs of auto-
immune responses such as changes in fur color or presence of
inflammatory infiltrates on tissue sections of liver, lung or colon.
Furthermore, immunohistochemistry staining for IgG complexes
on kidney sections did not reveal abnormalities. Blood cell counts
were normal in all groups of both models.
In summary, anti-CTLA4 expression from HSC progeny
increases the percentage of CD4+/CD1d+ cells in tumors, which
correlates with increased production of TGF-b1. Additionally, we
found less cytokines that are involved in the activation of anti-
Figure 7. Analysis of immune cells in tumors and spleens of mice treated with I-LV-aCTLA4 transduced HSCs and induction of
transgene expression by Dox by intraperitoneal injection. At day 28, tumors and spleens from Tx(I-LV-aCTLA4) and Tx(I-LV-aCTLA4)+Dox
mice were harvested and analyzed. A) Tumors infiltrating leukocytes and splenocytes were subjected to flow cytometry for Cd1d, CD4, CD25, and
NK1.1. N=3. B) Tumors were sectioned and stained with antibodies against CD1d (red) and CD4 (green) (upper panel) or CD1d (red) and NK1.1
(green) (lower panel). Representative sections are shown. The scale bar is 40 mm. C) Flow cytometry analysis of splenocytes. N=3. D)
Immunofluorescence analysis of spleen sections. upper panel: CD1d (red) and CD4 (green); lower panel: CD1d (red) and NK1.1 (green).
doi:10.1371/journal.pone.0022303.g007
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expressing tumors.
Discussion
Increased understanding of immune-regulatory mechanisms is
required for the development of new immunotherapy agents that
can modulate these signaling pathways and potentially break
tumor tolerance. In this study, we report two findings: i) systemic
delivery of anti-CTLA4 antibodies or intratumoral expression has
different effects in non-tolerized and tolerized mouse tumor
models and ii) HSC-mediated anti-CTLA4 expression triggers
immunosuppressive mechanisms, which facilitate tumor progres-
sion.
There is an emerging picture that the same mechanisms that
prevent autoimmunity also inhibit anti-tumor immune responses.
The central problem in cancer immunotherapy is that most TAAs
are non-mutated self-antigens that have triggered both central and
peripheral tolerance. It is therefore important to test new
immunotherapy approaches in mouse models, in which tolerance
against the inoculated tumor and specific TAAs exist. Central
tolerance is established by selection in the thymus: T-cells bearing
T-cell receptors with high affinity for self-antigen are eliminated
through apoptosis [38]. Additionally, peripheral T-cell tolerance is
required to suppress the remaining auto-reactive T-cells in the
periphery.
One goal of this study was to evaluate the anti-tumor effect of
anti-CTLA4 in a mouse model that resembled key features of
breast cancer in patients, most importantly tolerance to a TAA
(Neu) and the presence of Neu-reactive T-cells. Anti-CTLA4
delivery as a protein or expression from gene-modified tumor
cells were therapeutically efficacious in the non-tolerized TC-1
tumor model, but had no effect in the MMC-model, in spite of the
fact that anti-CTLA4 expression from MMC tumors increased the
number of Neu-specific T-cells. Neu-tg mice are tolerant to Neu.I t
has been discussed that in this model, subpopulations of high-
avidity Neu-specific T cells are deleted centrally, whereas T-cells
with lower avidity can leave the thymus but are subject to
peripheral mechanisms of tolerance [22,39]. This implies that
tolerance to Neu involves both central and peripheral mechanisms.
This finding suggests that the central tolerance mechanism must
be overcome to enable intra-tumoral Neu-specific T-cells to kill
tumor cells.
The model involving ex vivo transduced tumor cells is clinically
not relevant. We therefore assessed an approach that would allow
in vivo delivery of the anti-CTLA4 gene to the tumor. While viral
gene delivery to epithelial tumors is inefficient after systemic
application, recently a number of stem cell-based approaches have
shown more promise. Our stem cell gene delivery approach is
based on the ex vivo modification of HSCs, which home to the
tumor after transplantation and deliver therapeutic transgenes to
the tumor stroma. For HSC transduction, we used insulated SIN
lentivirus vector with Dox-inducible transgene expression. In
recent studies, we used the HSC-based approach to deliver the
relaxin gene to tumors [20,40]. In the MMC tumor model we
showed that this approach facilitates pre-existing anti-tumor T-
cells to control tumor growth. Furthermore, in xenograft models
with Her2/neu positive breast cancer cells, HSC-mediated relaxin
expression improved the anti-tumor efficacy of trastuzumab/
Herceptin [33]. However, unexpectedly, when used for anti-
CTLA4 gene delivery in this study, the HSC-gene approach was
therapeutically detrimental in both the TC-1 and MMC- models.
Anti-CTLA4 expression in these models triggered at least two
reactions. It increased the percentage of CD1d+ NKT cells in
tumors. These cells can theoretically activate myeloid suppressor
cells, which in turn, produce TGF-b1. In support of this, we found
,50-fold higher TGF-b1 mRNA levels in tumors of mice that
received anti-CTLA4-HSC gene therapy. Additionally, HSC-
based anti-CTLA4 gene delivery resulted in lower intratumoral
levels of cytokines (e.g. IL-1b) and chemokines (e.g. MIG, MIP-1,
RANTES) that stimulate immune responses. Proinflammatory
cytokines such as IL-1b create a milieu in the tumor that is
supportive for the activation of T- effector cells. Furthermore, a
number of cells of the immune system, including pre-cDCs, show
positive chemotaxis to CCL3 in a dose-dependent manner [41].
It remains in question, why expression of anti-CTLA4 from
TC-1 cells had a positive therapeutic effect, while anti-CTLA4
expression after HSC transplantation into C57Bl/6 mice did not.
Progeny of transplanted HSCs not only home to tumors and
differentiate into TAMs, but also reconstitute spleen, thymus, and,
potentially, macrophages in other tissues [20]. This implies that
anti-CTLA4 is also expressed in non-tumoral tissue, which could
have accounted for the unexpected outcome described above.
Based on recent evidence that TAMs have a unique gene
expression signature that distinguishes it from other tissue
macrophages [42], we are currently working on TAM-specific
expression systems to increase the tumor-specificity of transgene
expression.
Overall, these findings suggest that stem cell based delivery
methods, particularly for immuno-stimulatory genes, must ensure
homing of stem cells to tumors or exclusive expression within
tumors. The differences in outcomes between the tolerized and
non-tolerized models also provide a potential explanation for the
low efficacy of CTLA4 blockage approaches in cancer immuno-
therapy trials.
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